Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
CRXT and PTGX are leading our lists this morning
GNCA and GWGH are leading our pre-market stock movers today
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of...
Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.